# Gene Regulatory Networks: Modeling and Intervention

#### Ritwik Kumar Layek

Department of Electronics and Electrical Engineering Indian Institute of Technology Kharagpur, West Begal, India

October 30, 2013




#### Outline

- 1 Introduction
- 2 Dynamical Systems
- 3 CME
- 4 BN and PBN
- 5 Modeling
- 6 Intervention
- 7 Conclusion
- 8 References




#### The Cell

- Cell is the unit of life.
- The cell works as a massive signal processor.
- Dynamics of cell shows robust regulatory control.




#### DNA and RNA: The Helices of Life



000000

## Gene, Protein and Central Dogma of Molecular Biology



## Transcription Factor, Promoter and Genetic Regulation

- Transcription Factor (TF): Small proteins which binds the genomic DNA and initiates transcription.
- Promoter: The segment of the DNA where the transcription factor binds.
- Activator: This TF enhances the transcriptional activity.
- Inhibitor: This TF represses the transcriptional activity.
- Logic gate type behavior: For multiple TFs, the combined interaction can be like logic gates.


## Genetics and Epigenetics

- Gene: Sequence of DNA which encodes protein.
- Genetics: Study of the gene sequences and the effects of any alterations (mutations) in those genes.
- Epigenetics: Study of genetic expressions and regulatory behavior.
- All cells in an organism have identical genes (except mutant cells of course), but epigenetic programming plays the bigger role.
- Dynamical system modeling is required to describe the epigenetic interactions.




000000

## Modeling and Control




## Cell Cycle: Restriction Point

- Mitosis: Growth of a multi-cellular organism is achieved by Mitosis.
- Growth factors begin Mitosis.
- Differentiated cells divide only by special requests (example, PDGF)



## Transcriptional Network

- Protein synthesis is slow.
- The transcriptional network is usually shallow in terms of the signalling depth.
- The amino acids are reused by protein synthesis-degradation cycle.






## Signal Transduction Pathways

- Fast protein-protein interaction.
- The signal transduction pathways can be deep in terms of the signalling depth.
- They work in between transcriptional interactions.
- Transduction pathways can be modeled as combinatorial Boolean Network.
- Combining signal transduction with transcriptional (and post transcriptional) activity can lead to a better understanding of the system dynamics.



## Dynamical System Modeling: Different Paradigms



## Chemical Master Equation

- Stochastic Differential Equation with quantized state space.
- Markov Process
- CME can be derived from basic chemical kinetics and statistical physics [1].
- Consider a volume  $\Omega$  with N different species of molecules  $\{\psi_1, \psi_2, \psi_3, \dots, \psi_N\}$ .
- The counts of the molecules are  $\{x_1, x_2, x_3, \dots, x_N\}$ . Define the state (x) as this n-tuple.

## Chemical Master Equation: Parameters

- M elementary chemical reactions  $\{R_1, R_2, R_3, \dots, R_M\}$
- lacksquare  $a_{\mu}$ : Propensity function for the reaction  $R_{\mu}$
- $a_{\mu}(t)dt$  = Probability that the reaction  $R_{\mu}$  will happen in the time interval (t, t + dt)
- $\blacksquare R_{\mu} \Longrightarrow (x \longleftarrow x + s_{\mu})$
- Stoichiometric Matrix:  $S = [s_1, s_2, ..., s_M]$

- Suppose current state x(t) = x
- Given x,  $a_{\mu}(x)$  is computed for all  $R_{\mu}$
- $\blacksquare R_{\mu}: \psi_i \xrightarrow{c_{\mu}} \phi, a_{\mu}(x) = c_{\mu}x_i$
- $\blacksquare R_{ii}: \psi_i + \psi_i \xrightarrow{c_{\mu}} \phi, \ a_{ii}(x) = c_{ii}x_ix_i$
- $R_{ii}: \psi_i + \psi_i \xrightarrow{c_{\mu}} \phi, a_{ii}(x) = c_{ii}x_i(x_i 1)/2$

### Chemical Master Equation: Problem Formulation

- p(x,t): Probability that the chemical system will be in state x at time t
- CME: time evolution of p(x, t)

$$egin{array}{lll} & p(x,t+dt) & = & p(x,t)[1-\sum_{\mu=1}^{M}a_{\mu}(x)dt] \ & + & \sum_{\mu=1}^{M}p(x-s_{\mu},t)a_{\mu}(x-s_{\mu})dt \ & rac{p(x,t+dt)-p(x,t)}{dt} & = & -p(x,t)\sum_{\mu=1}^{M}a_{\mu}(x) \ & + & \sum_{\mu=1}^{M}p(x-s_{\mu},t)a_{\mu}(x-s_{\mu}) \end{array}$$

## Chemical Master Equation: Example

- $A + B \stackrel{k_1}{\rightleftharpoons} C$
- $\mathbf{x} = [X_A, X_B, X_C]$
- $s_1 = [-1, -1, 1], s_2 = [1, 1, -1]$
- $\bullet$   $a_1 = k_1 X_A X_B$ ,  $a_2 = k_2 X_C$
- Initial condition:  $x_0 = [4, 3, 0]$
- State space:  $\chi = \{(4,3,0), (3,2,1), (2,1,2), (1,0,3)\}$
- Probability space:  $\wp = \{p(4,3,0), p(3,2,1), p(2,1,2), p(1,0,3)\}$

## Chemical Master Equation: Example

- These four equations will govern the stochastic dynamics of the system.

## Stochastic Simulation Algorithm

- Objective: Dynamics x(t) not of p(x, t)
- Define  $p(\tau, \mu | x, t)$ : Probability (given x(t) = x) that the next reaction will occur in the time frame  $[t + \tau, t + \tau + d\tau]$  and the reaction will be  $R_{\mu}$
- $\blacksquare$  Time gap to the next reaction:  $\tau$
- Index of the next reaction:  $\mu$



#### SSA

- $P_0(\tau|x,t)$ : Probability that given x(t)=x, no reaction occurs in the interval  $[t,t+\tau)$
- $p(\tau, \mu | x, t) d\tau = P_0(\tau | x, t) a_{\mu}(x) d\tau$
- $P_0(\tau + d\tau | x, t) = P_0(\tau | x, t) [1 \sum_{\mu=1}^{M} a_{\mu}(x) d\tau]$
- $=\frac{dP_0(\tau|x,t)}{d\tau} = -P_0(\tau|x,t)\sum_{\mu=1}^M a_\mu(x) = -P_0(\tau|x,t)a_0(x)$
- Where,  $a_0(x) = \sum_{\mu=1}^{M} a_{\mu}(x)$
- $p(\tau|x,t) = e^{-a_0(x)\tau}$
- $p(\tau, \mu | x, t) = a_{\mu}(x)e^{-a_0(x)\tau}$
- Initial condition:  $P_0(0|x,t) = 1$
- $p(\tau, \mu | x, t) = [a_0(x)e^{-a_0(x)\tau}][\frac{a_\mu(x)}{a_0(x)}] = f(\tau)g(\mu)$



#### Monte Carlo Inversion Method

- $f(\tau)$ : Probability that next reaction will happen between time interval  $[t + \tau]$  and  $[t + \tau + d\tau]$ .
- **g**( $\mu$ ): Probability that given there is a reaction between time interval  $[t + \tau]$  and  $[t + \tau + d\tau]$ , the reaction will be  $R_{\mu}$
- Notice that  $\tau$  and  $\mu$  are conditionally independent given (x, t).
- Draw two uniform random variables  $r_1$  and  $r_2$  in the interval [0,1].



## Inversion Theory

- $x \sim p(x) \Rightarrow p(x')dx' = \text{probability that } x' \leq x \leq x' + dx'$
- $F(x) = \int_{-\infty}^{x} p(x') dx'$
- $F(x_0)$ : Probability that  $x \le x_0$
- Draw a random number  $r \sim U(0,1)$ . Find x which satisfies  $F(x_0) = r$  or  $x_0 = F^{-1}(r)$ . We need to prove that  $P(x_0 = x) = p(x)dx$
- Proof:  $P(x \le x_0 \le x + dx) = P\{F(x) \le r \le F(x + dx)\} = F(x + dx) F(x).$

## The Algorithm

- 1 Initialize at  $t = t_0$  and  $x = x_0$
- 2 Assuming x(t) = x, evaluate  $a_{\mu}(x)$ ,  $a_0(x)$
- f 3 Generate au,  $\mu$  according to the Monte Carlo Inversion Method
- 4  $t \leftarrow t + \tau$ ,  $x \leftarrow x + s_{\mu}$
- Return to step 2.

#### Markov Process and Markov Chain

- The CME is actually a Markov Process with huge state space.
- It is possible to reduce the state space by thresholding the protein concentrations.
- Many reactions follow Hill function kind of characteristics.
- Sampling the time axis reduces the Markov Process to Markov Chain. (Nyquist rate in Biology!)

## Markov Chain Properties

- Memoryless:  $P(x_{n+1} = x | x_n = y, x_{n-1} = z, ..., x_0 = w) = P(x_{n+1} = x | x_n = y)$
- Stationarity:  $P(x_{n+1} = x | x_n = y) = P(x_n = x | x_{n-1} = y)$
- n-step transition:  $p_{ij}^{(n)} = P(x_n = j | x_0 = i)$
- Chapman Kolmogorov Equation:  $p_{ij}^{(n+m)} = \sum_{k=1}^{M} p_{ik}^{(n)} p_{kj}^{(m)}$

## Markov Chain Properties..

- Marginal distribution:  $P(x_n = x) = \sum_{k=1}^{M} p_{ij}^{(n)} P(x_0 = i)$
- Accessibility:  $P(x_n = j | x_0 = i) = p_{ij}^{(n)} > 0$  for some  $n \ge 0$ . We say  $i \to j$
- Communicate: If  $i \rightarrow j$  and  $j \rightarrow i \Rightarrow i \leftrightarrow j$
- Irreducible: single communicating class.
- Periodicity (period k):  $k = gcd\{n : P(x_n = i | x_0 = i) > 0\}$
- Aperiodic: period = 1



## Markov Chain Properties..

- Hitting time:  $T_i = \inf\{n \ge 1 : x_n = i | x_0 = i\}$
- Transient:  $P(T_i < \infty) < 1$  or  $\sum_{n=0}^{\infty} p_{ii}^{(n)} < \infty$
- Recurrent:  $P(T_i < \infty) = 1$  or  $\sum_{n=0}^{\infty} p_{ii}^{(n)} = \infty$
- Absorbing state: If  $p_{ii} = 1$  and  $p_{ij} = 0 \ \forall \ i \neq j$
- Ergodic: A state is ergodic if it is positive recurrent and aperiodic. If all states of an irreducible MC is ergodic then the MC is ergodic.
- Steady state distribution:  $\pi_j = \sum_{i=1}^M \pi_i p_{ij}$



#### Boolean Network

- A Boolean Network(BN) B(V, F) is defined by a set of nodes  $V = \{x_1, x_2, \dots, x_n\}$  and a set of predictor functions  $F = \{f_1, f_2, \dots, f_n\}$ .
- A Boolean function  $f_i(V)$  determines the value of  $x_i$  in the next time instance.
- The Boolean rules generates the dynamics of the system.
- In BN, every state transits to an unique state.
- Some states are transient, whereas others are called the attractors.




#### Probabilistic Boolean Network


- A Probabilistic Boolean Network(PBN) B(V, F) is defined by a set of nodes  $V = \{x_1, x_2, ..., x_n\}$  and a set of predictor functions  $F = \{F_1, F_2, ..., F_n\}$ .
- A set of Boolean functions  $F_i(V) = f_i^j(V) \forall j = 1, 2, ..., l_i$  determines the value of  $x_i$  in the next time instance.
- The Boolean function  $f_i^j(V)$  is chosen with selection probability  $P_i^j$  such that  $\sum_{i=1}^{l_i} P_i^j = 1$
- In PBN, every state transits to different states according to a definite transition probability.



## State Transition Diagram



(a) Boolean Network (BN)



(b) Probabilistic Boolean Network (PBN)


#### Markov Chain and PBN

- It is evident that PBN is the structural representation of the Markov Chain.
- Inferring the constituent BNs, it is possible to know the 'Transition Probability Matrix' of the Markov Chain.
- Markov Chain is the missing link between the high level modeling of pathways and the low level modeling of molecular biochemistry.
- Markov Chain is also the most suitable model to design finite horizon optimal control in a biological framework.




## From Pathways to Networks[2]

- If the simplest model can capture the time dynamics try it first.
- p53 is an important transcription factor controlling the cell cycle and apoptosis.
- 50% of human cancers have p53 defect.




## P53 Regulatory Network


$$\begin{array}{rcl} ATM_{next} & = & \overline{Wip1}(ATM + dna\_dsb) \\ p53_{next} & = & \overline{Mdm2}(ATM + Wip1) \\ Wip1_{next} & = & p53 \\ Mdm2_{next} & = & \overline{ATM}(p53 + Wip1). \end{array} \tag{1}$$



## Steady state Behavior: No DNA damage




## Steady state Behavior: DNA damage



#### Indirect validation of P53-Mdm2 oscillation

 Prolonged (29 hrs) oscillations in the nuclear levels of fluorescently tagged p53-CFP (mapped to green) and Mdm2-YFP (mapped to red) in individual MCF7, U280, cells following 5 Gy gamma irradiation.




©Naama Geva-Zatorsky et al.




### Indirect validation of P53-ATM-Wip1 oscillation

■ Immunoblots of ATM-P(S1981), Chk2-P(T68), and p53 kinetics in MCF7 cells irradiated with 10Gy of g-irradiation.



Immunoblots of p53 and Wip1 kinetics in MCF7 cells irradiated with 10Gy of g-irradiation.



### New Discovery!

■ To find the missing piece of the puzzle




#### Green Fluorescent Protein

■ New Microscope of the 21<sup>st</sup> century biology!



Aequorea victoria



## Mutation: God doesn't play dice?

- Any alteration in the gene sequence during DNA synthesis is called mutation.
- Mutation implies changed behavior of the gene product (protein).
- Mutation can lead to constitutive activation, constitutive deactivation or unchanged behavior of the protein in a particular pathway.
- Changed behavior due to mutation can be modeled as stuck-at-1, stuck-at-0 faults.
- Mutation is the reason for both evolution and cancer.



### Cancer: Proliferation due to breakdown of the cell cycle

- Proliferation : Divide and conquer
- Apoptosis: Suicide is a crime
- Glycolysis: Save energy
- De-differentiation: Time machine
- Angiogenesis: Give me blood
- Invasion: Attack
- Increased motility: Move fast
- Decreased senescence: Forever young
- Metastasis: Immigrants
- Immortality: HeLa cell




## Winning against Cancer: Modeling is the key

- Chemotherapy: Mass destruction
- Targetted Therapy: Model the mutations and design drugs the revert the steady state response.
- Modeling
- Fault Detection
- Reporter Design
- Drug Design




### Growth Factor Mediated Pathways




## Growth Factor Mediated Pathways: Boolean Network

- The growth factor mediated signal transduction pathway is modeled as a combinatorial Boolean Network.
- These pathways don't show critical feedback loop.




### Fault and Drug Design

- All the possible faults which can lead to proliferation are enumerated.
- All the available drugs are modeled as inhibitory control.



### Single Fault Simulation

- Single fault simulation
- Equivalent fault classes




Output	Equivalent Fault Groups
11111111	1,2,3,4,5,6
0000111	7,8,9,10,11,12
0000000	0(No Fault),13,14,15
0111110	16,17,18
0000001	19
0000110	20,21,22,23,24

(b) Equivalent Faults for Input = 00001



### Optimal Therapeutic Intervention



# Importance of the Theoretical Result [5]


- The generalized fault detection approach can give us clue about reporter design.
- The drug simulation can eliminate the need of laboratory trials for many drug combinations.

#### Immediate extension

- Multiple fault modeling.
- Fault in feedback circuit.
- Intervention design to rectify the effects of these faults.
- Boolean Satisfiability problem: NP complete


#### Basins of Attraction

■ Control is required to change the basin of attraction



#### PBN revisited


- The most appropriate model for regulatory network is Markov Chain/Process.
- PBN is the most convenient model having both mathematical rigor and structural elegance.
- Transition Probability Matrix of an 'Instantaneously Random PBN' can be computed by weighted sum of the constituent BN's TPM.






#### control in Markov Chain

- In PBN environment control (drug) has to be applied periodically in a finite/infinite horizon window.
- Inhibitory control forcefully transits certain states.
- Essentially the TPM is changed during the therapeutic intervention.
- The objective is to move the state from undesirable basin of attraction to the desirable basin of attraction.




## Adaptive Controller Design

- Assumption: All the constituent model BNs are known.
- The estimator will sense the context and deploy the control accordingly.




# Simulation [7]

- Model tracking and cost tracking
- Almost sure convergence [6]



#### Personalized Medicine



#### Future Research

- Multiple fault detection in synchronous/asynchronous Boolean Network
- Multiple fault detection in Markov Chain/Markov Process
- Optimal observer design for detecting most of the faults
- Optimal drug design for Boolean Network/Markov Chain environment
- Wet Lab validation





A general method for numerically simulating the stochastic time evolution of coupled chemical reactions.

Journal of Computational Physics, 22:403–434, 1976.

R. Layek, A. Datta, and E. R. Dougherty. From biological pathways to regulatory networks. *Mol. BioSyst.*, 7:843–851, 2011.

E. Batchelor, A. Loewer, and G. Lahav. The ups and downs of p53: Understanding protein dynamics in single cells.

Nature Reviews: Cancer, 9(5):371–377, May 2009.

E. Batchelor, C. S. Mock, I. Bhan, A. Loewer, and G. Lahav. Recurrent initiation: A mechanism for triggering p53 pulses in response to dna damage.

Mol. Cell, 30(3):277-289, May 2008.



- R. Layek, A. Datta, M. Bittner, and E. R. Dougherty. Cancer therapy design based on pathway logic. *Bioinformatics*, 27(4):548–555, 2011.
- P. R. Kumar and W. Lin.
  Optimal adaptive controller for unknown markov chains.

  IEEE Trans. on Automatic Control, 27:765–774, 1982.
- R. Layek, A. Datta, R. Pal, and E. R. Dougherty. Adaptive intervention in probabilistic boolean networks. *Bioinformatics*, 25(16):2042–2048, 2009.







